MapLight Therapeutics (MPLT) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PepGen (PEPG) has outperformed MapLight Therapeutics (MPLT) over the past year, losing 32.0% versus a loss of 57.5%. PepGen is the larger company by market cap ($356.3 million vs $330.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MPLT | PEPG |
|---|---|---|
| Share price | $5.94 | $3.78 |
| Market cap | $330.12M | $356.31M |
| 1-day change | -7.48% | -3.82% |
| YTD return | -66.18% | -41.94% |
| 1-year return | -57.54% | -32.01% |
| EPS (TTM) | $-6.07 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-161.15M | $-89.66M |
| 52-week high | $40.43 | $7.80 |
| 52-week low | $5.93 | $1.31 |
| Distance from 52-week high | -85.31% | -51.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +340.24% | +263.76% |
| Average volume | 458.71K | 3.26M |
| Shares outstanding | 52.85M | 94.26M |
| Employees | 133 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed MPLT by 25.5 percentage points over the past year.
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
MPLT vs PEPG FAQ
Which is bigger, MapLight Therapeutics or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $330.12M for MapLight Therapeutics (MPLT).
Which stock has performed better over the past year, MPLT or PEPG?
PEPG returned -32.01% over the past 12 months, compared with -57.54% for MPLT (price return, excluding dividends). Past performance does not predict future results.
Are MapLight Therapeutics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.